Novo Nordisk Investigational Site

Debrecen H-4032

0 studies enrolling now · 21 studies all time

What they study most

Congenital Bleeding Disorder, Congenital FXIII Deficiency, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Haemophilia A, Haemophilia B, Inflammation, Metabolism and Nutrition Disorder, Obesity, Overweight, Rheumatoid Arthritis

Studies at this site

• Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity — Completed
• A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes — Completed
• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A — Completed
• A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs — Completed
• Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A — Completed
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A — Completed
• A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus — Completed
• Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. — Completed
• Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A — Completed
• Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study — Completed
• Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes — Completed
• The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy — Completed
• A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes — Completed
• Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin — Completed
• A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics — Stopped early
• Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes — Completed
• Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes — Completed
• A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms — Completed
• Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects — Completed
• Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds — Completed
• Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes — Completed